MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s44321-025-00293-5

Медицинская библиотека · EMBO molecular medicine · 2025

5-HT regulates resistance to aumolertinib by attenuating ferroptosis in lung adenocarcinoma.

Feng Yuanying, He Yuchao, Zuo Ran, Gong Wenchen, Gao Yuan, Wang Yun, Wang Yu, Chen Wenshuai, Chen Liwei, Luo Yi, Yuan Dongqi, Chen Peng, Guo Hua

СтатьяПеревод пока не подготовлен

Аннотация

Resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) remains a critical clinical challenge in EGFR mutant lung adenocarcinoma (LUAD). Therefore, it is urgent to explore personalized treatment strategies based on distinct resistance mechanisms to reverse EGFR-TKI resistance. Herein, we found that HER2 S310F mutation contributes to third-generation EGFR-TKI resistance, driven by the accumulation of neurotransmitter 5-hydroxytryptamine (5-HT). Mechanistically, 5-HT interacted with 5-HT3 receptor, triggering calcium ion (Ca2+) influx and subsequent activation of the Ca2+/CAMKK2/AMPK pathway. This pathway activation conferred ferroptosis resistance, thereby driving aumolertinib resistance. 5-HT3 receptor (HTR3) antagonists were pinpointed as potential agents for reversing aumolertinib resistance through drug library screening and transcriptomics analysis. We demonstrated that pharmacologically targeting 5-HT/HTR3 signaling with the clinically approved HTR3 antagonist palonosetron effectively restores aumolertinib sensitivity. Importantly, we showed that elevated 5-HT levels in patient plasma play a potential role in predicting EGFR-TKI resistance. Our data highlight the critical role of 5-HT and ferroptosis in the development of aumolertinib resistance, and propose HTR3 antagonists as a novel combination therapy strategy for LUAD treatment with aumolertinib.

Для цитирования: Feng Yuanying, He Yuchao, Zuo Ran, Gong Wenchen, Gao Yuan, Wang Yun, Wang Yu, Chen Wenshuai, Chen Liwei, Luo Yi, Yuan Dongqi, Chen Peng, Guo Hua. 5-HT regulates resistance to aumolertinib by attenuating ferroptosis in lung adenocarcinoma.. EMBO molecular medicine. 2025. DOI: 10.1038/s44321-025-00293-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.